Moxifloxacin: An 8-methoxy advanced generation fluoroquinolone that optimally inhibits both Topoisomerase II and Topoisomerase IV. The methoxy group at the C-8 position minimizes the selection of resistant mutants and broadens coverage against atypical, Gram-positive, and Gram-negative organisms in ocular infections.
Indications
Treatment of bacterial conjunctivitis caused by susceptible organisms
Superficial ocular bacterial infections as advised by the treating ophthalmologist
Note: This is an indicative Indication, please follow the doctors advise. Do not self medicate.
Dosage & Administration
Instill 1 drop into the inferior conjunctival cul-de-sac of the affected eye(s) as prescribed by the physician. Dosing frequency should be adjusted according to clinical response and severity.
Note: This is an indicative dosage, please follow the doctors advise. Do not self medicate.
References
1. Stroman DW, et al. In vitro and in vivo efficacy of moxifloxacin and gatifloxacin against ocular pathogens. Surv Ophthalmol. 2005;50 Suppl 1:S16-24.
2. O’Brien TP, et al. Antibacterial susceptibility of conjunctival bacterial isolates: A ten-year review. Clin Ophthalmol. 2007;1(3):341-348.
Warning: This information is only for the use of registered medical practitioners only.
Certified Manufacturing Standards
Disclaimer: This content is compiled from various references. We do not endorse any of it. Readers are advised not to self-medicate and to follow a doctor’s prescription and guidance.